Search results
Biogen and Sage to scrap neurological disorder drug development after trial failure - ET HealthWorld...
The Economic Times· 9 hours agoLondon: Biogen and Sage Therapeutics do not plan to conduct further studies for their neurological...
Biogen, Sage tremor drug fails key trial
BioPharma Dive· 10 hours agoIn 2020, Biogen wagered more than $1 billion on two experimental drugs developed in the labs of Sage Therapeutics, a fellow Cambridge,...
Autobahn raises $100M on investor interest in neuropsych drugs
BioPharma Dive· 11 hours agoNew investors included Canaan Partners, Monograph Capital, and Insight Partners, while Autobahn’s...
Nanotechnology in medicine: Who are the leading public companies?
Medical Device Network· 2 days agoApplications for nanotechnology in medicine include imaging, diagnosis, or the delivery of drugs...
Ionis plots next steps for Angelman drug Biogen passed on
BioPharma Dive· 2 days agoThe company plans to start a late-stage study next year, after a smaller trial found its drug...
Private biotech M&A surges amid difficult IPO market
BioPharma Dive· 2 days agoPrivate biotech company acquisitions are on their fastest pace in years, a trend some in the industry say is driven by the abundance of mature, but not...
Axsome Therapeutics’ AXS-05 shows promising results in treatment-resistant depression
Clinical Trials Arena· 3 days agoOn August 9, Axsome Therapeutics announced that its pipeline product AXS-05 (bupropion +...
Sage Therapeutics/Biogen’s episodic therapy zuranolone could change MDD treatment
Clinical Trials Arena· 3 days agoZuranolone: A Breakthrough in MDD Treatment by Sage Therapeutics and Biogen On June 15, new Sage...
